GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
The multi-billion, multi-year investment comes as many of GSK’s pharma peers pull away from the U.K., either suspending or ...
The FDA reapproved a GSK drug that stopped being sold more than 25 years ago, as part of a push to identify potential ...
GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug ...
GlaxoSmithKline has announced a $30 billion investment across US R&D and manufacturing over the next five years. Projects ...
The pharmaceutical company plans to break ground on a new manufacturing facility in Upper Merion, Pennsylvania, in 2026.
GSK plans a $30 billion investment in US R&D and manufacturing, including $1.2 billion for advanced facilities and AI ...
5don MSN
GSK commits $30 billion to US research and development, factory expansion, as Trump visits UK
Drugmaker GSK said Wednesday it would invest $30 billion in U.S. research and development and supply chain infrastructure ...
6don MSN
GSK adding a biologics factory in Upper Merion as part of a $1.2 billion investment in the U.S.
The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...
The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...
GSK is the latest Big Pharma company to announce plans to increase U.S. manufacturing capacity with the Trump administration ...
UK-headquartered pharmaceutical company GSK has announced plans to spend $1.2bn on manufacturing facilities and digital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback